Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is Parkman Healthcare Partners LLC's 9th Largest Position

Parkman Healthcare Partners LLC increased its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 16.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 755,244 shares of the company's stock after buying an additional 108,102 shares during the period. Kiniksa Pharmaceuticals accounts for 2.4% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 9th biggest position. Parkman Healthcare Partners LLC owned approximately 1.05% of Kiniksa Pharmaceuticals worth $18,874,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of KNSA. Vanguard Group Inc. grew its position in shares of Kiniksa Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company's stock valued at $58,833,000 after purchasing an additional 16,595 shares in the last quarter. SG Americas Securities LLC grew its position in Kiniksa Pharmaceuticals by 261.3% during the second quarter. SG Americas Securities LLC now owns 69,226 shares of the company's stock worth $1,292,000 after buying an additional 50,066 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Kiniksa Pharmaceuticals by 45.7% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 181,966 shares of the company's stock worth $3,397,000 after buying an additional 57,088 shares in the last quarter. Bank of New York Mellon Corp grew its position in Kiniksa Pharmaceuticals by 2.3% during the second quarter. Bank of New York Mellon Corp now owns 115,143 shares of the company's stock worth $2,150,000 after buying an additional 2,563 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Kiniksa Pharmaceuticals by 6.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 64,943 shares of the company's stock worth $1,212,000 after buying an additional 3,837 shares in the last quarter. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ KNSA traded down $0.04 during midday trading on Wednesday, reaching $21.13. The company had a trading volume of 326,413 shares, compared to its average volume of 402,221. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.56 and a one year high of $28.15. The firm's fifty day moving average price is $23.83 and its 200-day moving average price is $23.00. The stock has a market cap of $1.53 billion, a PE ratio of -150.85 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. During the same period last year, the firm posted ($0.20) EPS. The company's revenue was up 67.4% on a year-over-year basis. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on KNSA. Jefferies Financial Group began coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a "buy" rating and a $40.00 target price for the company. Evercore ISI lifted their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has an average rating of "Buy" and an average target price of $36.60.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 17,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares of the company's stock, valued at approximately $2,955,028.25. This represents a 13.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 54.57% of the stock is currently owned by corporate insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.